Skip to main content
Equibles
PNTG logo

PNTG · Pennant Group, Inc.

Track PNTG — free

Use PNTG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PNTG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$36.07 +0.16 (+0.45%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$1.27B
Shares
35.13M
Volume · Nov 13 420.07K Avg daily vol (3M) 368.68K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$36.07 Open$35.91 Day$35.46–37.16 52W close$24.89–44.04 Avg vol 30d416K Short int1.2M · 3.3% of shares · 4.1d Short vol51% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Next earnings call
Feb 25, 2027 Est · unconfirmed · in 15 wks
Q3 2026 earnings call transcript
call held Nov 5, 2026
Play latest call

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue and operating income increased

The Pennant Group, Inc. reported nine-month revenue of 885,599 thousand and operating income of 50,999 thousand for 2026, versus 658,382 thousand and 34,416 thousand in 2025. It added seven senior living communities during the nine months ended September 30, 2026.

Revenue $302.25M ▲ 32.0% Net income $9.64M ▲ 58.5% Diluted EPS $0.26 ▲ 52.9%
Read from the MD&A section
6 source passages
The Pennant Group, Inc. Three Months Ended September 30, | Nine Months Ended September 30, | 2026 | 2025 | 2026 | 2025 (In thousands) Total revenue | 302,251 | 229,039 | 885,599 | 658,382 Income from operations | 16,512 | 10,238 | 50,999 | 34,416 During the nine months ended September 30, 2026, we expanded our operations with the addition of seven senior living communities. Open the document at this passage
Nov 4
Current report 8-K
Third-quarter revenue rises 32.0% to $302.3 million

Pennant Group, Inc. reported third-quarter revenue of $302.3 million, up 32.0% year over year, GAAP diluted earnings per share of $0.26 and adjusted diluted earnings per share of $0.35 for the quarter ended September 30, 2026.

Financial results, Regulation FD disclosure
3 source passages
The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.26 for the third quarter of 2026. Pennant also reported adjusted diluted earnings per share of $0.35 for the quarter(1). Total revenue for the third quarter was $302.3 million, an increase of $73.2 million or 32.0% over the prior year quarter; On November 4, 2026, The Pennant Group, Inc. (the “Company”) issued a press release reporting the financial results of the Company for its third quarter ended September 30, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.17B
Trailing 12 months
Net income (TTM)
$35.88M
Trailing 12 months
Revenue growth YoY
+32.0%
Year over year
Operating margin
5.8%
Trailing 12 months
P / E (TTM)
36.1
Trailing earnings · reciprocal yield 2.8%
FCF yield
2.7%
TTM · current market cap
Return on invested capital
8.6%
Trailing 12 months
Net cash
−$174.94M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.2%
Year over year · more shares
Price change (1Y)
+44.9%
Trailing year
Short interest
3.3%
Latest settlement · 4.1 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲29.4% $188.89M $5.76M '24 Q4* ▲33.7% $209.84M $7.78M '25 Q1 ▲30.1% $219.50M $7.08M '25 Q2 ▲26.8% $229.04M $6.08M '25 Q3 ▲53.2% $289.32M $8.64M '25 Q4* ▲36% $285.36M $8.52M '26 Q1 ▲35.8% $297.98M $9.08M '26 Q2 LATEST ▲32% $302.25M $9.64M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Pennant (PNTG) delivered strong Q2 2026 results, raising full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EBITDA prior to NCI, and adjusted EPS, with the home health proposed 2027 rate and ongoing Southeast acquisition transition underpinning the outlook.

Bullish
  • + Strong Q2 revenue and adjusted EBITDA growth versus prior year quarter
  • + 2027 proposed home health rule includes a 2.4% rate increase (modeled as 1.7%) after four consecutive years of base rate cuts
  • + Home health and hospice segment revenue up 43.2% and segment adjusted EBITDA up 48.2% with 70 bps same-store margin improvement
  • + Strong same-store organic growth: same-store hospice ADC +10.8%, same-store Medicare home health admissions +13.6%
Bearish
  • − Home health revenue per episode declined 1.9% year over year
  • − Ongoing integration disruption from largest acquisition in company history continues through October
  • − Outstanding credit facility balance of $201.9 million; debt increased driven by Hartford investment

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +0%
above
Price vs 50-day avg −10%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 58%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −14%
trailing
6-month return +6%
trailing
YTD return +28%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $40 › 200d $36 — 50d above 200d
Institutional flow Distributing
181 of 202 funds reported for Sep 30 · net -547.0K sh shares · +29 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.33% of shares out · ▲ +2.0% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
202 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Strong
Revenue growth +36%
Y/Y
EPS growth +20%
Y/Y
Free cash flow $36.3M
Valuation P/E 36.1
rich
Buyback $1.0M
authorized
Balance sheet $151.8M
net debt
Quant / Vol
risk profile
High
Volatility 40%
annualized · 1-yr
Max drawdown −18%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the Earnings Call filed Aug 6, 2026
Full year total revenue · full year 2026 Maintained $1.17B – $1.19B
Aug 5, 2026 $1.17B – $1.19B changed to Aug 6, 2026 $1.17B – $1.19B
prior FY $947.71M midpoint +24.5% Y/Y
Full year adjusted diluted earnings per share · full year 2026 Non-GAAP Maintained $1.34 – $1.41
Aug 5, 2026 $1.34 – $1.41 changed to Aug 6, 2026 $1.34 – $1.41
Full year adjusted EBITDA prior to NCI · full year 2026 Non-GAAP Maintained $101.5M – $105.1M
Aug 5, 2026 $101.5M – $105.1M changed to Aug 6, 2026 $101.5M – $105.1M
Full year adjusted EBITDA · full year 2026 Non-GAAP Maintained $94.4M – $98M
Aug 5, 2026 $94.4M – $98M changed to Aug 6, 2026 $94.4M – $98M
Previous outlook earlier release · from the Earnings Call filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Capital expenditures · for the year $15M – $18M
Guided vs delivered · last 5 settled
Total revenue full year 2025
guided $911.4M – $948.6M
$947.71M In line
Total revenue full year 2024
guided $654M – $694.5M
$695.24M Beat +3.1%
Total revenue 2022 annual
guided $458M – $462M
$473.24M Beat +2.9%
Revenue full year 2021
guided $430M – $440M
$439.69M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+0% Bullish
Price vs 50-day avg
−10% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
58% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $40 › 200d $36 — 50d above 200d
Institutional flow Distributing
181 of 202 funds reported for Sep 30 · net -547.0K sh shares · +29 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.33% of shares out · ▲ +2.0% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
202 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $25 Now $36 · 58% Range high $44
vs 200-day avg +0% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Diluted Earnings Per Share non-GAAP $0.68 Six Months Ended June 30, 2026 —
Adjusted net income non-GAAP $12.8M second quarter of 2026 —
Average daily census 5,339 Six Months Ended June 30, 2026 —
Average daily hospice census 5,477 Three Months Ended June 30, 2026 filing —
Average hospice daily census 5,477 the three months ended June 30, 2026 filing —
Average Medicare revenue per 60-day completed episode $3,689 Six Months Ended June 30, 2026 —
Average monthly revenue per occupied room $5,392 second quarter of 2026 —
Consolidated Adjusted EBITDA non-GAAP $45.98M Six Months Ended June 30, 2026 —
Consolidated Adjusted EBITDA prior to NCI non-GAAP $49.57M Six Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Consolidated Adjusted EBITDA 24.27M
+1.82M Add: Net Income attributable to noncontrolling interest ("NCI")
= Consolidated Adjusted EBITDA prior to NCI 26.08M
Consolidated Adjusted EBITDAR non-GAAP $72.37M Six Months Ended June 30, 2026 —
Consolidated EBITDA non-GAAP $37.48M Six Months Ended June 30, 2026 —
Home Health and Hospice Services segment adjusted EBITDA from operations prior to NCI non-GAAP $39.6M second quarter of 2026 —
Home Health and Hospice Services segment adjusted EBITDAR from operations non-GAAP $41M second quarter of 2026 —
Hospice average daily census 5,477 second quarter of 2026 —
Hospice Medicare revenue per day $191 Six Months Ended June 30, 2026 —
Non-GAAP net income non-GAAP $24.37M Six Months Ended June 30, 2026 —
Number of home health and hospice agencies at period end 175 Three Months Ended June 30, 2026 filing —
Number of senior living communities at period end 69 Three Months Ended June 30, 2026 filing —
Occupancy 78.7% Six Months Ended June 30, 2026 —
Same store average monthly revenue per occupied room $5,413 second quarter of 2026 —
Same store average occupancy 81.6% second quarter of 2026 —
Same store home health admissions 17,854 second quarter of 2026 —
Same store hospice average daily census 4,089 second quarter of 2026 —
Same store Medicare home health admissions 7,372 second quarter of 2026 —
Segment Adjusted EBITDA from Operations - Home health and hospice services non-GAAP 71.33M Six Months Ended June 30, 2026 —
Segment Adjusted EBITDA from Operations - Senior living services non-GAAP 12.25M Six Months Ended June 30, 2026 —
Segment Adjusted EBITDAR from Operations non-GAAP 109.98M Six Months Ended June 30, 2026 —
Segment Adjusted EBITDAR from Operations - Home Health and Hospice non-GAAP 77.75M Six Months Ended June 30, 2026 —
Segment Adjusted EBITDAR from Operations - Senior Living non-GAAP 32.23M Six Months Ended June 30, 2026 —
Senior Living segment adjusted EBITDA from operations non-GAAP $5.8M second quarter of 2026 —
Senior Living segment adjusted EBITDAR from operations non-GAAP $16M second quarter of 2026 —
Total home health admissions 59,668 Six Months Ended June 30, 2026 —
Total hospice admissions 4,844 Three Months Ended June 30, 2026 —
Total Medicare home health admissions 25,219 Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PNTG
Pennant Group, Inc.
this stock
$1.27B +28.1% +36.3% 36.1 3.3%
HCA
HCA Healthcare, Inc.
 $104.25B +6.9% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
 $33.34B +3.3% — — 0.0%
THC
Tenet Healthcare Corp
 $22.76B +43.9% +0.9% 8.3 2.2%
EHC
Encompass Health Corp
 $13.83B +32.8% +10.5% 22.0 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
216
% held
88.6%
Reported
181 of 202
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
217
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
4.1d
Change
+23.2K sh
View
Short Volume
Short vol %
51%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
15.4K
Value
$622.8K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
43.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$947.7M
Net income (FY)
$29.6M
EPS diluted
$0.84
View
Buybacks
Authorized
$1.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
11

Pennant Group, Inc. reported third-quarter revenue of $302.3 million, up 32.0% year over year, GAAP diluted earnings per share of $0.26 and adjusted diluted earnings per share of $0.35 for the quarter ended September 30, 2026.

View
Proposed Sales
Value
$165.1K
Shares
4.3K
Filed
Aug 6, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Pennant Announces Third Quarter 2…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
PNTG -0.8% -13.9% +6.3% -13.4% +28.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -3.4% -12.7% +5.8% -13.2% +17.5%

Capital returns

Buyback program · as of Dec 12, 2022
Authorized
$1.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1766400 CUSIP 70805E109 13F (30d) 173 filings 158 filers Visit website Investor relations